Xencor (XNCR) Operating Expenses (2013 - 2026)
Xencor (XNCR) posted quarterly Operating Expenses of $82.4 million for Q1 2026, up 8.51% year-over-year from $75.9 million in Q1 2025, and up 0.63% quarter-over-quarter from $81.9 million in Q4 2025.
Analysis
Xencor (XNCR) Operating Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Operating Expenses for 14 consecutive years, with $82.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 8.51% year-over-year to $82.4 million; the TTM figure through Mar 2026 stood at $309.5 million (up 5.23% YoY), while the FY2025 annual figure was $303.1 million, up 4.91% from the prior year.
- Operating Expenses improved to $82.4 million in Q1 2026 per XNCR's latest filing, from $81.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $82.4 million in Q1 2026 and bottomed at $58.2 million in Q2 2022.
- Historically, Operating Expenses has averaged $72.3 million across 5 years, with a median of $73.0 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Expenses soared 32.69% — and 2024, when it decreased 17.22%.
- Xencor's Operating Expenses stood at $64.2 million in 2022, then rose by 24.13% to $79.7 million in 2023, then fell by 17.22% to $66.0 million in 2024, then grew by 24.09% to $81.9 million in 2025, then rose by 0.63% to $82.4 million in 2026.
- Business Quant data shows XNCR's Operating Expenses at $82.4 million in Q1 2026, $81.9 million in Q4 2025, and $68.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.05 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 960.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 505.13 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 1.21 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 541.02 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Xencor | 2.01 Bn | 1.64 Bn | - | 88.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 88.29 Mn |
| Mar 31, 2026 | 82.38 Mn |
| Dec 31, 2025 | 81.87 Mn |
| Sep 30, 2025 | 68.52 Mn |
| Jun 30, 2025 | 76.78 Mn |
| Mar 31, 2025 | 75.92 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Sep 30, 2024 | 72.99 Mn |
| Jun 30, 2024 | 79.28 Mn |
| Mar 31, 2024 | 70.66 Mn |
| Dec 31, 2023 | 79.70 Mn |
| Sep 30, 2023 | 77.43 Mn |
| Jun 30, 2023 | 71.52 Mn |
| Mar 31, 2023 | 78.33 Mn |
| Dec 31, 2022 | 64.20 Mn |
| Sep 30, 2022 | 65.65 Mn |
| Jun 30, 2022 | 58.18 Mn |
| Mar 31, 2022 | 59.03 Mn |
| Dec 31, 2021 | 62.36 Mn |
| Sep 30, 2021 | 60.98 Mn |